A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant (007)

• ClinicalTrials.gov Identifier: NCT02540330
• Recruitment Status: Terminated
• First Posted: September 3, 2015
• Results First Posted: April 5, 2022
• Last Update Posted: April 5, 2022
• Sponsor: Atossa Genetics, Inc.
• Information provided by (Responsible Party): Atossa Genetics, Inc.

Study Description

Brief Summary:

This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS. The first subject of each of five groups will receive fulvestrant intramuscularly. The subsequent 5 subjects of each group will receive fulvestrant by intraductal instillation. All subjects will be monitored for systemic and local adverse events during the procedure, and following the procedure until mastectomy or lumpectomy. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.

Condition or disease	Intervention/treatment	Phase
Female Breast Carcinoma; Female Ductal Carcinoma In Situ	Drug: Fulvestrant	Phase 2

Detailed Description:

This is an open-label, non-randomized pharmacokinetic study of pre-surgical fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified upon admission to the institution for surgical management of breast cancer or DCIS, specifically mastectomy or lumpectomy. There will be 5 groups, each consisting of 6 subjects. The first subject of each group will receive fulvestrant administered intramuscularly and the next 5 subjects will receive fulvestrant intraductally. Subjects where at least 1 suitable duct is identified may undergo nipple aspiration in order to facilitate duct identification and intraductal infusion of a fulvestrant accompanied by imaging (saline+ ultrasound). A maximum of 5 ducts will receive intraductal infusion of fulvestrant. Across all ducts, the total dose will not exceed 500 mg (10 mL). All subjects will be monitored for systemic and local adverse events during the procedure, immediately following the procedure, within 30 minutes, 1 hour, 4 hours and by phone following discharge on Days +1 and +2, +7, and pre-operative. Subsequent to mastectomy or lumpectomy, subjects will be assessed for systemic adverse events until discharge. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 3 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy
• Actual Study Start Date: March 2016
• Actual Primary Completion Date: August 13, 2020
• Actual Study Completion Date: August 13, 2020

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Intramuscular Fulvestrant; 500mg fulvestrant administered intramuscularly	Drug: Fulvestrant; Other Name: Faslodex
Experimental: Intraductal Fulvestrant; up to 500mg fulvestrant administered intraductally	Drug: Fulvestrant; Other Name: Faslodex

Outcome Measures

Primary Outcome Measures :

1. Safety and Tolerability of Two Delivery Methods [ Time Frame: Up to 4 weeks ]
   Number of adverse events per CTCAE v4.0 after treatment with fulvestrant by route of administration

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Female
2. 18 years of age or older
3. Scheduled to undergo non-nipple sparing mastectomy for Invasive Breast Cancer or DCIS
4. Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ requiring mastectomy or lumpectomy
5. Estrogen Receptor-positive pathology
6. ECOG performance scale of 0-1

7. Adequate organ function as defined by the following criteria:

   • Absolute neutrophil count (ANC) ≥ 1500/μl
   • Platelets ≥ 100,000/μl
   • Hemoglobin ≥ 9.0 g/dl
   • Creatinine ≤ 2 times upper limit of normal
   • Bilirubin ≤ 2 times upper limit of normal
   • Transaminases (AST/SGOT and ALT/SGPT) ≤ 2.5 times upper limit of normal
8. Able to sign informed consent
9. Willing to use effective contraception for at least 100 days post study drug administration.

Exclusion Criteria:

1. Concurrent treatment with another anti-estrogen
2. Presence of an active infection requiring systemic therapy

3. The following conditions contra-indicating fulvestrant administration:

   1. Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant use (excluding aspirin and anti-inflammatories)
   2. Subjects with a known hypersensitivity to fulvestrant or any of its formulation components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate.
   3. Severe hepatic impairment.
4. Prior surgery on the ipsilateral breast which interrupts communication of the ductal systems with the nipple
5. Prior radiation to the breast
6. Pregnant or lactating
7. Impaired cardiac function or history of cardiac problems of NYHA Class 111 and IV
8. Poor nutritional state as indicated by a BMI below 20.
9. Presence of serious infection not controlled with systemic therapy
10. History of allergies to Lidocaine or Novocain
11. Concurrent participation in an experimental drug study

Contacts and Locations

Locations

United States, Maryland

The Johns Hopkins School of Medicine

Baltimore, Maryland, United States, 21205

United States, New York

Montefiore Medical Center

New York, New York, United States, 10461

Sponsors and Collaborators

Atossa Genetics, Inc.

Investigators

• Study Chair: Steven C Quay; Atossa Therapeutics, Inc.

  Study Documents (Full-Text)

Documents provided by Atossa Genetics, Inc.:

Study Protocol and Statistical Analysis Plan  [PDF] January 6, 2020

More Information

• Responsible Party: Atossa Genetics, Inc.
• ClinicalTrials.gov Identifier: NCT02540330
• Other Study ID Numbers: ATOS-2015-007
• First Posted: September 3, 2015
• Results First Posted: April 5, 2022
• Last Update Posted: April 5, 2022
• Last Verified: March 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Carcinoma; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Breast Diseases; Skin Diseases; Adenocarcinoma; Neoplasms, Ductal, Lobular, and Medullary; Breast Carcinoma In Situ; Fulvestrant; Antineoplastic Agents, Hormonal; Antineoplastic Agents; Estrogen Receptor Antagonists; Estrogen Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs